PACE-CME

Targeting triglyceride-rich remnant lipoproteins

Targeting triglyceriderich remnant lipoproteins
RestartResume
10' education - Dec. 21, 2021 - Prof. Daniel Gaudet, MD, PhD

Subtitles: German, Italian, 简体中 & more

  • Overview

    Prof. Daniel Gaudet gives an overview of emerging therapies targeting triglyceride-rich remnant lipoproteins. With question to test your knowledge.

  • Educational information

    This lecture by Daniel Gaudet is part of a series titled "Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities".

    This program has been designed to educate physicians and other healthcare professionals with an interest in CV risk on lipid-associated residual risk beyond LDL-c and provide an update of novel findings in basic and clinical science with regard to the association of triglyceride-rich remnant lipoproteins and CV risk. In addition, guidance will be given how to use findings from studies on triglyceride-rich lipoproteins in the treatment of patients in clinical practice.

  • Faculty

    Prof. Daniel Gaudet, MD, PhD - Clinical Lipidology and Rare Lipid Disorders Unit, CMGC Department of Medicine, Université de Montréal, QC, Canada

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant received from Pfizer Inc.

    Click here for the meeting report

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free